HIE
stage |
Apgar
score (at 1 minute) |
|
Range |
Median |
|
Stage
I |
2-5 |
4.00 |
Stage
II |
1-4 |
3.00 |
Stage
III |
1-3 |
2.00 |
Inference |
As
the Apgar score decreases the HIE stage increase with p<0.001** |
|
Organ involvement |
Number (n=92) |
Percentage% |
Group 0 |
No organ involvement |
32 |
34.8 |
Group 1 |
One organ involvement |
10 |
10.9 |
Group 2 |
Two or more organ
involvement |
50 |
54.3 |
Organ
involvement (other
than CNS) |
Stage
1 (n=33) |
Stage
2 (n=18) |
Stage
3 (n=8) |
Total |
No
organ involved |
10
(30.30) |
- |
- |
10 |
One
organ involved |
18
(54.54) |
02
(11.11) |
- |
20 |
Two
organs involved |
03
(09.09) |
07
(38.89) |
- |
10 |
Three
organs involved |
02
(06.07) |
07
(38.89) |
- |
09 |
Four
organs involved |
- |
02
(11.11) |
08
(100) |
10 |
Total |
33
(100) |
18(100) |
8
(100) |
59 |
Perinatal factors |
|
|
HIE |
|
p value |
|
|
||||||||||
Yes (n=59) |
|
No (n=33) |
|
|
|||||||||||||
|
|
|
|
|
|
||||||||||||
Parity |
Primigravida |
32 |
|
|
19 |
0.757 |
|
|
|||||||||
Multigravida |
27 |
|
|
14 |
|
||||||||||||
|
|
|
|
|
|||||||||||||
MSAF |
Yes |
31 |
|
|
20 |
0.455 |
|
|
|||||||||
No |
28 |
|
|
13 |
|
||||||||||||
|
|
|
|
|
|||||||||||||
PIH |
Yes |
8 |
|
7 |
0.341 |
|
|
|
|||||||||
No |
51 |
|
|
26 |
|
|
|
||||||||||
|
|
|
|
|
|||||||||||||
APH |
Yes |
2 |
|
|
1 |
0.999 |
|
|
|
||||||||
No |
57 |
|
|
32 |
|
|
|
|
|||||||||
|
|
|
|
|
|
||||||||||||
PROM |
Yes |
8 |
|
1 |
|
0.150 |
|
|
|
||||||||
No |
51 |
|
|
32 |
|
|
|||||||||||
|
|
|
|
|
|
||||||||||||
Anemia |
Yes |
5 |
|
|
11 |
0.003** |
|
|
|
||||||||
No |
54 |
|
|
22 |
|
|
|||||||||||
|
|
|
|
|
|
||||||||||||
Duration of II stage |
Normal |
58 |
|
|
22 |
|
|
|
|
||||||||
Prolonged |
1 |
|
|
11 |
<0.001** |
|
|
||||||||||
|
|
|
|
|
|
||||||||||||
Cord Prolapse |
Yes |
1 |
|
|
0 |
|
0.999 |
|
|
||||||||
No |
58 |
|
|
33 |
|
|
|
|
|||||||||
|
|
|
|
|
|
||||||||||||
Mode of Delivery |
Spontaneous |
30 |
|
|
15 |
0.620 |
|
|
|
||||||||
Instrumental |
9 |
|
0 |
0.024* |
|
|
|
||||||||||
|
LSCS |
20 |
|
|
18 |
0.054 |
|
|
|||||||||
Fetal heart rate abnormalities |
Normal |
38 |
|
|
33 |
0.022 |
|
||||||||||
Fetal tachycardia (H.R>160) |
3 |
|
|
0 |
|||||||||||||
Fetal bradycardia (H.R<100) |
18 |
|
|
0 |
Neonatal
|
HIE |
p value |
||
Yes(no=59) |
No(no=33) |
|||
Inborn/outborn |
Inborn |
23 |
15 |
0.545 |
Outborn |
36 |
18 |
||
Gender |
Male |
34 |
14 |
0.161 |
Female |
25 |
19 |
||
Weight
for gestational age |
SGA |
17 |
7 |
0.426 |
AGA |
38 |
22 |
0.827 |
|
LGA |
04 |
4 |
0.451 |
|
Presentation |
Vertex |
55 |
29 |
0.451 |
Breech |
4 |
4 |
||
Gestational Maturity |
Term |
56 |
33 |
0.550 |
Post term |
3 |
0 |
||
(APGAR SCORE) Perinatal asphyxia |
Mild /Moderate |
51 |
33 |
<0.001* |
Severe |
8 |
0 |
||
pH |
>7.2(normal) |
2 |
20 |
<0.003* |
7-7.2(moderate
acidemia) |
45 |
13 |
||
<7(severe
acidemia) |
12 |
0 |
S
No. |
Study |
HIE
followingperinatal hypoxia |
1 |
Present study |
64.13% |
2 |
Martin
Ancel et al[6] |
72% |
3 |
Gonzalez
de DJ, Moya M[10] |
25.6% |
4 |
Thornberg
et al[11] |
33.03% |
S No. |
Study |
HIE
Stage I |
HIE
Stage II |
HIE
Stage III |
1 |
Present
study |
55.93% |
30.51% |
13.56% |
2 |
Martin
Ancel et al[6] |
57.7% |
28.8% |
13.5% |
3 |
Gonzalez
de DJ, Moya M[10] |
75% |
12.5% |
12.5% |
4 |
Robertson
C, Finer N[12] |
39.5% |
56.3% |
4.2% |
5 |
FunayamaCA[13]et al |
45.7% |
42.5% |
11.8% |
Present
study |
HIE
Stage I |
HIE
Stage II |
HIE
Stage III |
Death |
---- |
1
(5.6%) |
5
(62.5%) |
Persistingneurological
abnormality |
---- |
4
(22.2%) |
3
(37.5%) |
S No |
Study |
Renal |
Pulmonary |
CVS |
GIT |
1 |
Present study |
46.7% |
21.7% |
23.9% |
25.0% |
2 |
Martin
Ancel et al[6] |
42% |
26% |
29% |
29% |
3 |
Perlman
JM et al[17] |
50% |
23% |
25% |
- |
4 |
Shah
P et al[20] |
70% |
86% |
62% |
- |
|
Present
study |
Martin
Anceletal[6] |
Perlman
JM et al[19] |
Group
0 |
34.8% |
18% |
34% |
Group
1 |
10.9% |
26% |
23% |
Group
2 |
54.3% |
55% |
43% |